{"filings":[{"id":93478,"accession_number":"0001193125-26-208959","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.","Interventional Dry Eye revenue $1.4M (+244% YoY, +87% QoQ); Glaucoma revenue $18.3M (+7% YoY).","FY 2026 revenue guidance raised to $83M-$89M from $82M-$88M; adj. opex reaffirmed $93M-$96M.","Final Alcon judgment: $55.4M past damages + 10% ongoing royalty for Hydrus patent infringement (subject to appeal)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":19698000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93477,"accession_number":"0001193125-26-171887","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sight Sciences wins patent case vs Alcon; awarded $55.4M damages + ongoing royalty","event_type":"litigation","confidence":"high","bullets":["Final judgment in Sight Sciences' patent infringement case against Alcon for Hydrus Microstent.","Award totals $55.4M: $34.0M past damages, $14.7M supplemental, $6.8M interest through April 17, 2026.","Ongoing royalty of 10% of Hydrus revenue through expiration of last patent.","Judgment is subject to appeal; Alcon's ex parte reexamination proceedings could affect collection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105133,"accession_number":"0001193125-26-130386","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sight Sciences secures court order preserving willful-infringement verdict against Alcon; $34M award plus royalties","event_type":"litigation","confidence":"high","bullets":["Order upholds jury finding that Alcon willfully infringed three Sight Sciences patents.","Past damages of $34M ($5.5M lost profits + $28.5M royalties) plus supplemental damages and interest.","Ongoing royalty of 10% of Hydrus revenue through November 10, 2028 (last patent expiry).","Final judgment expected in months; subject to appeal and possible USPTO reexamination impact.","Company to record $5.4M success fee to Cooley LLP, excluded from non-GAAP operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105132,"accession_number":"0001193125-26-091482","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.","Q4 net loss $4.2M ($0.08 loss per share) vs $11.8M loss in Q4 2024; full-year net loss $38.4M vs $51.5M.","Cash $92M at Dec 31, 2025; Q4 cash used only $0.4M; full-year cash used $28.4M.","FY 2026 guidance: revenue $82-88M (+6-14% YoY); Glaucoma $77-81M; Dry Eye $5-7M.","Operating expenses down 25% Q4 and 13% full-year; adjusted op ex guidance $93-96M for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105131,"accession_number":"0001193125-26-035915","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sight Sciences amends headquarters lease, extends term to December 2028","event_type":"other","confidence":"high","bullets":["Second Amendment to lease extends term 26 months from Nov 1, 2026 to Dec 31, 2028.","Rent abated Nov-Dec 2026; then $44,915.45/mo through Oct 2027.","Base rent increases to $46,214.21/mo Nov 2027-Oct 2028, then $47,621.20/mo through Dec 2028.","Lessor is Deerfield Campbell, LLC; lease covers Suites 100 and 120 at 4040 Campbell Avenue, Menlo Park."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105130,"accession_number":"0001193125-26-011106","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.","Full year 2025 revenue $77.3M-$77.4M, down 3% vs 2024; Surgical Glaucoma flat, Dry Eye ~$1.6M (from $4.0M).","Cash and equivalents ~$92M; Q4 cash burn ~$0.4M, FY cash used ~$28M.","Management reiterates path to cash flow breakeven without additional equity; complete results expected March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":77363000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121386,"accession_number":"0001193125-25-269525","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO","event_type":"earnings","confidence":"high","bullets":["Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.","Net loss narrowed to $8.2M ($0.16 loss per share) from $11.1M loss in Q3 2024.","Raises FY2025 revenue guidance to $76-78M (from $72-76M); reduces adj. op. expense guidance to $90-92M.","Promoted Alison Bauerlein to COO from CFO, James Rodberg to CFO, effective Nov 5, 2025.","Board members Becker and Rogers resigned; board size reduced from 9 to 7."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":56978000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121385,"accession_number":"0001193125-25-241948","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sight Sciences gets Medicare pricing for TearCare from Novitas and FCSO; $1,141.59 fee","event_type":"regulatory","confidence":"high","bullets":["Two MACs set jurisdiction-wide pricing for CPT 0563T (TearCare) at $1,141.59, effective Jan 1, 2025.","Covers 10.4M estimated Medicare lives (~30% of FFS beneficiaries) across multiple states.","Company plans to provide updated revenue and adjusted opex guidance on Q3 2025 earnings call.","Sight Access Portal launched to assist providers with benefit verifications and prior authorizations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138040,"accession_number":"0001193125-25-225041","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sight Sciences extends interest-only period to Feb 2027, ups Tranche 3 to $25M","event_type":"debt","confidence":"high","bullets":["Interest-only period extended six months to February 1, 2027.","Tranche 3 availability increased from $15M to $25M, drawable in $5M increments subject to Hercules' sole approval.","Company paid $50,000 amendment fee plus expenses; total $65M facility unchanged.","Performance Milestone II and Interest Only Extension Conditions removed from loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138039,"accession_number":"0001531177-25-000007","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["2.05","5.02","7.01"],"status":"ready","headline":"Sight Sciences cuts 20% workforce; CCO departs; reaffirms FY revenue guidance","event_type":"other_material","confidence":"high","bullets":["Reduces headcount by 43 (~20% of global workforce); expects cash restructuring charge of $2.7M-$3.0M in Q3 2025.","CCO Matthew Link steps down effective Aug 31; eligible for severance including 1-year base salary and vesting of 61,675 RSUs.","Reaffirms FY2025 revenue guidance of $72M-$76M; updates adjusted opex guidance to $95M-$99M from $101M-$105M.","Annualized savings of ~$11.9M from workforce reductions alone.","Creates segment-specific leadership for Surgical Glaucoma and Dry Eye; delays certain R&D spend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138038,"accession_number":"0000950170-25-105012","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.","Surgical Glaucoma revenue $19.2M (-5% YoY); ordering accounts hit record 1,174, up 4%.","Dry Eye revenue fell to $0.3M from $1.1M as company focuses on reimbursed TearCare access.","Adjusted operating expenses $24.4M, down 8% YoY; reaffirmed FY25 guidance of $101-105M.","Tariff exposure on China products reduced from prior estimate of $3.5-4.5M to $1.0-1.5M for FY25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":37072000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155439,"accession_number":"0001193125-25-135930","cik":1531177,"company_name":"Sight Sciences, Inc.","ticker":"SGHT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Sight Sciences appoints Gerhard Burbach to Board; annual meeting elects directors and ratifies auditor","event_type":"leadership","confidence":"high","bullets":["Gerhard F. Burbach appointed to Board and Audit Committee (appointment previously disclosed April 21, 2025).","Annual meeting held June 5, 2025 with 75.1% of shares represented; three Class I directors elected.","Directors elected: Paul Badawi (24,675,076 for), Brenda Becker (20,923,888 for), Erica Rogers (23,914,492 for).","Ratification of Deloitte & Touche as independent auditor for FY2025 passed (38,080,605 for, 26,937 against, 706,687 abstain).","No other matters were presented or voted upon at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}